How Sun Pharma Clinched Ranbaxy – The Inside Story
This article was originally published in PharmAsia News
Executive Summary
Sun Pharma’s Dilip Shanghvi bought out Ranbaxy to push ahead in the fast-evolving global generics industry. In contrast to wide speculation that the Ranbaxy deal was inked over a short time, bankers who spoke to PharmAsia News divulged a well-planned and studied move that began as early as in 2012 and culminated into the final agreement now.
You may also be interested in...
Ranbaxy’s $500 Million GMP Settlement Would Be Second Most Expensive For Rx Manufacturing Violations
Ranbaxy Laboratories said it has signed a consent decree with FDA and set aside $500 million to settle a related Department of Justice investigation involving GMP violations and data integrity issues at its Indian facilities.
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.